Lilly Beats Expectations, Raises Guidance

Lilly completed the CoLucid acquisition in March.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is reporting first quarter net income of $1.2 billion, compared to a loss of $110.8 million during the same period the previous year. The company has also raised its full-year earnings per share and revenue expectations, driven in part by new products, including Trulicity, Taltz and Cyramza.

Lilly is reporting first quarter worldwide revenue of $5.7 billion, which is a 9 percent increase over the first quarter of 2017. The company says the increase was driven by favorable foreign exchange rates, higher realized prices and a volume increase. U.S. revenue increased 8 percent to $3.16 billion.

The drugmaker has increased its full-year revenue forecast to a range of $23.7 billion-$24.2 billion from a previous range of $23 billion-$23.5 billion. It has also raised its full-year earnings per share expectations from a range of $4.81-$4.91 per share to a range of $5.10-$5.20 per share.

The company is also reporting mixed news on its product front. Lilly and Incyte Corp. (Nasdaq: INCY) say the U.S. Food and Drug Administration’s Arthritis Advisory Committee has recommended approval of a two-milligram dose of baricitinib for the treatment of rheumatoid arthritis. The committee voted against recommending a four-milligram dose.

You can see more on Lilly’s first quarter earnings report by clicking here.